NCT05800093Completed
Proteomics and Genomics Combined With CT to Predict CVD
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 312 (actual)
- First submitted
- 13 Mar 2023
- Start date
- 12 Jan 2023
- Primary completion date
- 8 Apr 2026
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Diseases
- Coronary artery disease
- NCT number
- NCT05800093
What you commit to
- Study type: Observational
- Participants enrolled: 312
- From 12 Jan 2023 to the primary completion date, 8 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
- Change in lipid lowering therapy in the last 6 months
Other illness
- History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
- Active malignancy requiring treatment
- Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
Lab values
- Renal insufficiency, defined as eGFR \< 30 ml/min
Other
- Use of more than two antihypertensive agents
- No coronary atherosclerosis at baseline imaging
- Atrial fibrillation
- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Who the study is looking for
- Adult patients between 50 and 75 years old
- Subjects at intermediate to high risk for ASCVD
- Asymptomatic patients without cardiac chest pain
- Evidence of atherosclerosis on baseline CCTA
Age in the registry: 50 years to 75 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC, location AMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.